Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Iodohippurate→

Iodohippurate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
147-58-0
Molecular formula
C9H8INO3
Molecular weight
305.07 g/mol
Drug class
Diagnostic radiopharmaceuticalrenal tubular secretion and effective renal plasma-flow imaging agent when radioiodinated
Mechanism of action
Radioiodinated orthoiodohippurate is cleared predominantly from the circulation by active secretion through organic anion transporters in the proximal renal tubules, with a smaller contribution from glomerular filtration. Renal uptake and clearance are measured by scintigraphy.
Indications / reported uses
  • Dynamic renal scintigraphy to assess renal perfusion, effective renal plasma flow, tubular extraction and urinary drainage in selected diagnostic protocols.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6020824/ · https://sites.snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2018/Renal%20Scintigraphy_Blaufox_0318.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Iodohippurate Environmental Risk Assessment (ERA) (the Iodohippurate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.